Elevated antidrug antibodies against atezolizumab and associated clinical outcomes in advanced non-small-cell lung cancer
High ADA levels were linked to lower atezolizumab exposure and worse outcomes. ADA monitoring may help predict prognosis and guide immunotherapy strategies.
Authors
- So Jung Kong (ORCID: https://orcid.org/0000-0002-8988-8258)
- Se‐Hoon Lee (ORCID: https://orcid.org/0000-0002-9219-3350)
- Hong Jae Chon (ORCID: https://orcid.org/0000-0002-6979-5812)
- Hannah Yang (ORCID: https://orcid.org/0000-0003-2252-7041)
- Chan Kim (ORCID: https://orcid.org/0000-0001-9780-6155)
- Won Suk Lee (ORCID: https://orcid.org/0000-0003-2753-5294)
- Ho Yun Lee (ORCID: https://orcid.org/0000-0001-9960-5648)
- Miran Jang (ORCID: https://orcid.org/0000-0002-5046-161X)
Institutions
- Samsung Medical Center (KR)
- CHA University Bundang Medical Center (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1007/s00262-025-04245-3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- Korea Institute of Science and Technology
- Korea Institute of Science and Technology Information
- Korea Health Industry Development Institute
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea
- Korea Research Environment Open Network
- Samsung
- Advanced Research Projects Agency
- Great Southern Development Commission, Government of Western Australia